Gsa Capital Partners LLP Cyma Bay Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

$1.43 Billion
Q2 2024

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$5.88 - $9.59 $287,302 - $468,576	-48,861 Reduced 73.66%	17,468 $152,000
Q4 2022 Feb 13, 2023	SELL	$3.22 - $6.27 $105,294 - $205,029	-32,700 Reduced 33.02%	66,329 $416,000
Q3 2022 Nov 14, 2022	BUY	$2.77 - $4.25 $102,032 - $156,548	36,835 Added 59.23%	99,029 $347,000
Q2 2022 Aug 09, 2022	SELL	$1.72 - $3.39 $223,686 - $440,869	-130,050 Reduced 67.65%	62,194 $183,000
Q1 2022 May 11, 2022	SELL	$2.77 - $3.64 $105,298 - $138,370	-38,014 Reduced 16.51%	192,244 $598,000
Q4 2021 Feb 14, 2022	SELL	$3.23 - $4.6 $109,710 - $156,243	-33,966 Reduced 12.86%	230,258 $778,000
Q3 2021 Nov 12, 2021	BUY	$3.47 - $4.42 $463,425 - $590,299	133,552 Added 102.2%	264,224 $964,000
Q2 2021 Aug 05, 2021	SELL	$3.94 - $4.92 $219,241 - $273,773	-55,645 Reduced 29.87%	130,672 $570,000
Q1 2021 May 10, 2021	BUY	$4.23 - $6.55 $141,789 - $219,556	33,520 Added 21.94%	186,317 $846,000
Q4 2020 Feb 03, 2021	BUY	$5.73 - $9.03 $875,526 - $1.38 Million	152,797 New	152,797 $877,000
Q1 2020 May 12, 2020	SELL	$1.25 - $2.02 $246,612 - $398,525	-197,290 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$1.33 - $5.93 $201,078 - $896,538	151,187 Added 327.93%	197,290 $387,000
Q3 2019 Nov 12, 2019	BUY	$5.12 - $7.21 $19,548 - $27,527	3,818 Added 9.03%	46,103 $236,000
Q2 2019 Aug 06, 2019	BUY	$6.05 - $13.66 $255,824 - $577,613	42,285 New	42,285 $303,000
Q4 2018 Feb 12, 2019	SELL	$6.54 - $11.74 $408,750 - $733,750	-62,500 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$10.88 - $14.52 $680,000 - $907,500	62,500 New	62,500 $693,000
Q1 2018 May 11, 2018	SELL	$9.0 - $15.16 $595,800 - $1 Million	-66,200 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$7.67 - $9.31 $651,183 - $790,419	-84,900 Reduced 56.19%	66,200 $609,000
Q3 2017 Nov 20, 2017	BUY	$5.95 - $8.26 $899,045 - $1.25 Million	151,100	151,100 $1.22 Million

Others Institutions Holding CBAY

# of Institutions

Shares Held

1.82M

Call Options Held

Put Options Held

View Full List

About CymaBay Therapeutics, Inc.

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

More about CBAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account